What it sells
Neural interfaces to understand and use nerve data in medicine.
Business model breakdown
Buyer: who owns the budget?
UnverifiedR&D and clinical development leaders at pharma and bioelectronic device companies.
Trigger: what makes them buy now?
Slow feedback on drug efficacy and dosing; BIOS claims cutting efficacy feedback from months to minutes.
Workflow: what inputs become what output?
Neural recording interface plus AI for biomarker discovery, patient stratification, automated stimulation settings and remote outcome metrics via wearables.
Economics: what it saves and how it charges
Long-term co-development partnerships on neural digital therapies; claims 15x faster discovery and optimal dose in under 10 minutes.
Distribution: how it reaches customers
Direct partnership sales via Contact the BIOS team.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2017 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.